Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

1.

The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.

Bilodeau MT, Rodman LD, McGaughey GB, Coll KE, Koester TJ, Hoffman WF, Hungate RW, Kendall RL, McFall RC, Rickert KW, Rutledge RZ, Thomas KA.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2941-5.

PMID:
15125964
[PubMed - indexed for MEDLINE]
2.

2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitors.

Manley PJ, Balitza AE, Bilodeau MT, Coll KE, Hartman GD, McFall RC, Rickert KW, Rodman LD, Thomas KA.

Bioorg Med Chem Lett. 2003 May 19;13(10):1673-7.

PMID:
12729639
[PubMed - indexed for MEDLINE]
3.

Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.

Du J, Lei B, Qin J, Liu H, Yao X.

J Mol Graph Model. 2009 Jan;27(5):642-54. doi: 10.1016/j.jmgm.2008.10.006. Epub 2008 Nov 5.

PMID:
19081278
[PubMed - indexed for MEDLINE]
4.

Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.

Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R Sr, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ.

J Med Chem. 2006 Jun 29;49(13):3766-9.

PMID:
16789733
[PubMed - indexed for MEDLINE]
5.

Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.

Ruel R, Thibeault C, L'Heureux A, Martel A, Cai ZW, Wei D, Qian L, Barrish JC, Mathur A, D'Arienzo C, Hunt JT, Kamath A, Marathe P, Zhang Y, Derbin G, Wautlet B, Mortillo S, Jeyaseelan R Sr, Henley B, Tejwani R, Bhide RS, Trainor GL, Fargnoli J, Lombardo LJ.

Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9. doi: 10.1016/j.bmcl.2008.03.057. Epub 2008 Mar 22.

PMID:
18395443
[PubMed - indexed for MEDLINE]
6.

Property-based design of KDR kinase inhibitors.

Fraley ME, Hoffman WF, Arrington KL, Hungate RW, Hartman GD, McFall RC, Coll KE, Rickert K, Thomas KA, McGaughey GB.

Curr Med Chem. 2004 Mar;11(6):709-19. Review.

PMID:
15032725
[PubMed - indexed for MEDLINE]
7.

Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

Kuo GH, Prouty C, Wang A, Emanuel S, Deangelis A, Zhang Y, Song F, Beall L, Connolly PJ, Karnachi P, Chen X, Gruninger RH, Sechler J, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.

J Med Chem. 2005 Jul 28;48(15):4892-909.

PMID:
16033269
[PubMed - indexed for MEDLINE]
8.

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.

Tavares FX, Boucheron JA, Dickerson SH, Griffin RJ, Preugschat F, Thomson SA, Wang TY, Zhou HQ.

J Med Chem. 2004 Sep 9;47(19):4716-30.

PMID:
15341487
[PubMed - indexed for MEDLINE]
9.

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.

Wissner A, Floyd MB, Johnson BD, Fraser H, Ingalls C, Nittoli T, Dushin RG, Discafani C, Nilakantan R, Marini J, Ravi M, Cheung K, Tan X, Musto S, Annable T, Siegel MM, Loganzo F.

J Med Chem. 2005 Dec 1;48(24):7560-81.

PMID:
16302797
[PubMed - indexed for MEDLINE]
10.

2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.

Kiselyov AS, Semenova M, Semenov VV, Piatnitski E.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1726-30. Epub 2005 Dec 20.

PMID:
16364640
[PubMed - indexed for MEDLINE]
11.

Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.

Fraley ME, Arrington KL, Hambaugh SR, Hoffman WF, Cunningham AM, Young MB, Hungate RW, Tebben AJ, Rutledge RZ, Kendall RL, Huckle WR, McFall RC, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):2973-6.

PMID:
12941314
[PubMed - indexed for MEDLINE]
12.

Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.

Wu Z, Fraley ME, Bilodeau MT, Kaufman ML, Tasber ES, Balitza AE, Hartman GD, Coll KE, Rickert K, Shipman J, Shi B, Sepp-Lorenzino L, Thomas KA.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):909-12.

PMID:
15012992
[PubMed - indexed for MEDLINE]
13.

Discovery of a series of aminopiperidines as novel iNOS inhibitors.

Le Bourdonnec B, Leister LK, Ajello CA, Cassel JA, Seida PR, O'Hare H, Gu M, Chu GH, Tuthill PA, DeHaven RN, Dolle RE.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43. Epub 2007 Oct 25.

PMID:
18024030
[PubMed - indexed for MEDLINE]
14.

Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives.

Aoki K, Obata T, Yamazaki Y, Mori Y, Hirokawa H, Koseki J, Hattori T, Niitsu K, Takeda S, Aburada M, Miyamoto K.

Chem Pharm Bull (Tokyo). 2007 Feb;55(2):255-67.

PMID:
17268099
[PubMed - indexed for MEDLINE]
Free Article
15.

Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.

Bilodeau MT, Cunningham AM, Koester TJ, Ciecko PA, Coll KE, Huckle WR, Hungate RW, Kendall RL, McFall RC, Mao X, Rutledge RZ, Thomas KA.

Bioorg Med Chem Lett. 2003 Aug 4;13(15):2485-8.

PMID:
12852948
[PubMed - indexed for MEDLINE]
16.

Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.

Yu H, Wang Z, Zhang L, Zhang J, Huang Q.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33. Epub 2007 Feb 2.

PMID:
17306530
[PubMed - indexed for MEDLINE]
17.

Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

Wissner A, Fraser HL, Ingalls CL, Dushin RG, Floyd MB, Cheung K, Nittoli T, Ravi MR, Tan X, Loganzo F.

Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. Epub 2007 Mar 23.

PMID:
17416531
[PubMed - indexed for MEDLINE]
18.

Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.

Choquette D, Teffera Y, Polverino A, Harmange JC.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4054-8. doi: 10.1016/j.bmcl.2008.05.114. Epub 2008 Jun 4.

PMID:
18573658
[PubMed - indexed for MEDLINE]
19.

1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.

Tripathy R, Ghose A, Singh J, Bacon ER, Angeles TS, Yang SX, Albom MS, Aimone LD, Herman JL, Mallamo JP.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1793-8. Epub 2006 Dec 21.

PMID:
17239587
[PubMed - indexed for MEDLINE]
20.

Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.

Boyer SJ.

Curr Top Med Chem. 2002 Sep;2(9):973-1000. Review.

PMID:
12171566
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk